WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Mohammad Mokhber: Who is Iran’s acting president?
Pump the brakes! US safety regulator announces HUGE change to all new cars and trucks
Royal Family jokes about the Natural History Museum's 'Rex
Huge change to NHS prescriptions kicks in today as pharmacists warn of a 'dark day' for patients
Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
Less alcohol, or none at all, is one path to better health
UNC's RJ Davis is returning to school for a 5th season. He was an AP 1st
Ricky Stenhouse punching Kyle Busch could lead to suspension
A man who failed to get asylum in the UK is said to have voluntarily flown to Rwanda
Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
Mexican volunteer searchers say they've found a clandestine crematorium in Mexico City